[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Submit :: Contact Us ::
:: Volume 7, Issue 3 ( Autumn 2017) ::
J Fasa Univ Med Sci 2017, 7(3): 353-360 Back to browse issues page
Investigating the Combination therapy effect of Trastuzumab and Idarubicin on growth inhibition of HER2-positive breast cancer cells line (SK-BR-3)
Moslem Afrakhteh 1, Majid Zeinali 2, MohammadAli Ghaffari 1, Aminollah Pourshohod 1, Mostafa Jamalan 3
1- Department of Clinical Biochemistry, Cellular and Molecular Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2- Biotechnology Research Center, Research Institute of Petroleum Industry (RIPI), Tehran, Iran , zeinalim@ripi.ir
3- Department of Clinical Biochemistry, Cellular and Molecular Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.Abadan School of Medical Sciences, Abadan, Iran
Abstract:   (235 Views)

Background & Objectives: Trastuzumab and Idarubicin (4-methyl-daunorubicin) are two anti-neoplasmic agents that are widely used in cancer therapy. Idarubicin is more lipophilic than its parent drugs such as daunorubicin, therefore  it is absorbed more efficiently by the target cells. The main aim of this study was to Investigate the combinational effect of Trastuzumab (as anti-HER2 monoclonal antibody) and Idarubicin on growth inhibition of HER2 positive breast cancer cells.
Material & Methods: In this study, SK-BR-3 cell line as HER2-positive and MCF-7 as cell line with low-level of expression of HER2 were used for treatment process. After 72 hours incubation treatment with various concentrations of indicated agents, induced cytotoxicity of various concentrations of idarubicin, trastuzumab, and idarubicin-trastuzumab as combination was assessed by MTT assay.
Results: the results showed that Idarubicin discretely induced similar effect on both cell lines but trastuzumab as it expected induced its effect based on the level of HER2 expression and thus inhibited SK-BR-3 cell line growth in a more potent manner. Between all of treatment methods, idarubicin-trastuzumab therapy was the most efficient and specific treatment for the  reduction of cell viability of SK-BR-3 cells as HER2-positive cell line compared to CMF-7 cell line. Indicated combination therapy,  reduced viability of SK-BR-3 cells to 17% in comparison with  MCF-7 cell line  in similar conditions, and induced a significant (p≤0.01) SK-BR-3 cell death compared to  MCF-7 cells.
Conclusion: It seems that idarubicin combination therapy with trastuzumab in HER2-positive breast cancer cells can be used as an alternative effective treatment.
 

Keywords: Idarubicin, Trastuzumab (Herceptin), Breast Cancer, Combinational Therapy, HER2
Full-Text [PDF 1180 kb]   (55 Downloads)    
Type of Study: Research | Subject: Oncology
Received: 2016/10/30 | Accepted: 2017/05/24 | Published: 2017/11/26
Send email to the article author

Add your comments about this article
Your username or Email:

Write the security code in the box >



XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Afrakhteh M, zeinali M, Ghaffari M, Pourshohod A, Jamalan M. Investigating the Combination therapy effect of Trastuzumab and Idarubicin on growth inhibition of HER2-positive breast cancer cells line (SK-BR-3). J Fasa Univ Med Sci. 2017; 7 (3) :353-360
URL: http://journal.fums.ac.ir/article-1-1270-en.html
Volume 7, Issue 3 ( Autumn 2017) Back to browse issues page
Journal of Fasa University of Medical Sciences
Persian site map - English site map - Created in 0.049 seconds with 803 queries by yektaweb 3571